This bilingual event was hosted in Japanese, and included translated presentations from expert Lhasa and Consult Lhasa scientists.
Experts David Ponting (Principal Scientist, Lhasa Limited) and Natan Segretti (CSO, Consult Lhasa) presented an explorative webinar on the recently updated EMA guidelines for nitrosoureas risk assessment.
Natan provided a comprehensive overview of this critical regulatory update, explaining why nitrosoureas are classified within the cohort of concern and the reasoning behind these new regulatory changes.
Following this, David delivered a practical demonstration of our in silico read-across tool, Acrostic. Through a detailed nitrosourea case study, attendees witnessed first hand how the software can be effectively utilised to determine acceptable intake limits for nitrosoureas in accordance with the latest EMA requirements.
What attendees learnt:
- A comprehensive understanding of the updated EMA guidelines on nitrosoureas and why these compounds require regulatory attention.
- Practical insights into applying in silico read-across methodology for nitrosoureas evaluation using Acrostic.
- Effective strategies for establishing evidence-based acceptable intake limits that align with regulatory expectations while supporting your scientific goal.